Volition Proudly Sponsors the 44th ISICEM Congress

Volition to host multiple presentations at the International Symposium on Intensive Care & Emergency Medicine in Brussels, Belgium, from March 18 - 21 , /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISICEM ("International Symposium on Intensive Care & Emergency Medicine") Congress in Brussels Belgium being held from March 18-21. As a silver sponsor, Volition will support multiple presentations highlighting the Company's Nu.Q® H3.1 epigenetic screening technology in intensive care and emergency medicine settings. Dr. Andrew Retter, Chief Medical Officer at Volition, commented: "Volition is thrilled to be a supporting presence at the 44th Annual ISICEM Congress. This year is exceptionally exciting for Volition as multiple groundbreaking studies that validate the crucial role of NETosis, NETs, and specifically nucleosomes-H3.1 in the screening, monitoring, and early intervention of sepsis in ICU settings are being presented. "These developments open the door to a tremendous $1B+ market opportunity in sepsis care alone, positioning Volition at the forefront of this revolutionary advancement in critical care medicine. Most importantly there is increasing evidence that monitoring H3.1 nucleosome is a new tool which may improve patient outcomes." Presentations featuring Nu.Q® H3.1 at the congress: Presentation 1Date and Time: Tuesday, March 18, 2025, at 2:30 pmTopic: "Circulating NETs levels"Speaker: Professor Djillali AnnaneLocation: Panoramic Room Presentation 2Date and Time: Wednesday, March 19, 2025, at 9:45 amTopic: "Functional endotyping in sepsis"Speaker: Professor Evangelos Giamarellos-BourboulisLocation: 100 Hall Presentation 3Date and Time: Wednesday, March 19, 2025, at 1:45 pmTopic: "Neutrophils in host response and organ dysfunction"Speaker: Professor Michael BauerLocation: Arc room Presentation 4Date and Time: Wednesday, March 19, 2025, at 3:35 pmTopic: "The Time for Precision has Come"Speaker: Professor Evangelos Giamarellos-BourboulisLocation: Arc room Presentation 5Date and Time: Thursday, March 20, 2025, at 10:00 amTopic: "H3.1 for early recognition of sepsis"Speaker: Professor Djillali AnnaneLocation: 100 Hall Presentation 6Date and Time: Thursday, March 20, 2025, at 11:00 amTopic: "NETosis an important predictor of organ dysfunctionSpeaker: Dr. Lieuwe BosLocation: 100 Hall Additionally, Dr. Andrew Retter, Critical Care Lead and Chief Medical Officer of Volition is an invited speaker for the Praetorian Doctoral Network Satellite Symposium at ISICEM, March 19th, 2025, the session will take place at 11:35 am. The session topic, "Nu.Q® test to measure levels of circulating H3.1 nucleosomes as a surrogate marker for neutrophil extracellular traps (NETs) in blood." The project PRAETORIAN Network (EuroPean Training NetwoRks to TArget DAMPs and NETs: novel apprOaches in pRecision SepsIs pAtieNt care) is set up to train 10 doctoral candidates who will collaboratively work to develop novel approaches in precision sepsis patient care providing new diagnostics and therapeutics to answer to an urgent unmet clinical need. About ISICEM The ISICEM annual congress is one of the largest Intensive Care conferences in its field, attracting more than 5,000 participants from countries worldwide. The aim of ISICEM is to improve the care of the critically ill patient through better clinical management, by facilitating ongoing education and training of all healthcare staff involved in patient care and supporting and encouraging constructive research in the field. The hope is that every person who attends one of their events will learn something new and useful that they can take back to their units and share with colleagues to improve the practice of intensive care and ultimately patient outcomes. About Volition Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life. Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and London. The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only. Media Enquiries: Louise Batchelor, Volition, [email protected] +44 (0)7557 774620 Investor Relations Jeremy Feffer, LifeSci Advisors, [email protected] +1-212-915-2568 Safe Harbor Statement Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances. Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. SOURCE VolitionRx Limited WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Volition Proudly Sponsors the 44th ISICEM Congress

FAQ

Why Bullish?

How important is it?

Why Long Term?

Related Companies

Related News